Direct-acting Antiviral Drug Market Research Report by Type (NS3/4A Protease, NS5A Protein, and NS5B RNA-Dependent RNA polymerase), by Indication (HIV Infection/ AIDS, Hepatitis C Virus, and Influenza), by Route, by Distribution Channel, by Region (Americ

Direct-acting Antiviral Drug Market Research Report by Type (NS3/4A Protease, NS5A Protein, and NS5B RNA-Dependent RNA polymerase), by Indication (HIV Infection/ AIDS, Hepatitis C Virus, and Influenza), by Route, by Distribution Channel, by Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2026 - Cumulative Impact of COVID-19

The Global Direct-acting Antiviral Drug Market size was estimated at USD 7,208.33 million in 2020 and expected to reach USD 8,239.12 million in 2021, at a CAGR 13.86% to reach USD 15,706.07 million by 2026.

Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.


Market Segmentation & Coverage:

This research report categorizes the Direct-acting Antiviral Drug to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Type, the market was studied across NS3/4A Protease, NS5A Protein, and NS5B RNA-Dependent RNA polymerase.

Based on Indication, the market was studied across HIV Infection/ AIDS, Hepatitis C Virus, Influenza, and Prophylaxis.

Based on Route, the market was studied across Intravenous, Oral, Subcutaneous, and Topical.

Based on Distribution Channel, the market was studied across Hospital Pharmacy, Online Drug Store, and Retail Pharmacy.

Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Direct-acting Antiviral Drug Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Direct-acting Antiviral Drug Market, including A-S Medication Solutions, Actavis Group Ptc Ehf., Agouron Pharmaceuticals, Aizant Drug Research Solutions Pvt Ltd, Amneal Pharmaceuticals LLC, Apotex Corporation, Atea Pharmaceuticals, Inc., Auro Pharma Inc, Boehringer Ingelheim Pharmaceuticals Inc., Bristol-Myers Squibb Company, Camber Pharmaceuticals, Inc., Cipla USA Inc., E.R. Squibb & Sons, L.L.C., F. Hoffmann-La Roche, Genentech, Inc., H.J. Harkins Company, Jamp Pharma Corporation, Marcan Pharmaceuticals Inc, Merck Ltd., Mylan N.V., New American Therapeutics, Inc, Novartis, PD-Rx Pharmaceuticals, Inc., Pfizer Inc., Physicians Total Care, Inc., Prestium Pharma, Inc., Remedy Repack, Sciegen Pharmaceuticals Inc., and Teva Pharmaceuticals USA, Inc..

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Direct-acting Antiviral Drug Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Direct-acting Antiviral Drug Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Direct-acting Antiviral Drug Market?
4. What is the competitive strategic window for opportunities in the Global Direct-acting Antiviral Drug Market?
5. What are the technology trends and regulatory frameworks in the Global Direct-acting Antiviral Drug Market?
6. What is the market share of the leading vendors in the Global Direct-acting Antiviral Drug Market?
7. What modes and strategic moves are considered suitable for entering the Global Direct-acting Antiviral Drug Market?


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
3.1. Introduction
4. Market Overview
4.1. Introduction
4.2. Cumulative Impact of COVID-19
5. Market Dynamics
5.1. Introduction
5.2. Drivers
5.2.1. Increasing prevalence and incidence of hepatocellular carcinoma and liver cirrhosis
5.2.2. Increasing product development and launch of new direct-acting antiviral medicines
5.2.3. Growing awareness and improving healthcare outlook in emerging countries
5.3. Restraints
5.3.1. Difficulties in obtaining insurance approval for new HCV treatment regimens
5.3.2. High cost of drugs
5.4. Opportunities
5.4.1. Increasing support from government authorities & social healthcare associations
5.4.2. Availability of directly-acting antivirals medicines and strategic collaborations
5.5. Challenges
5.5.1. Patent expiration of branded direct-acting antiviral
5.5.2. unmeasured side effects associated with the Direct-Acting Antiviral drugs
6. Direct-acting Antiviral Drug Market, by Type
6.1. Introduction
6.2. NS3/4A Protease
6.3. NS5A Protein
6.4. NS5B RNA-Dependent RNA polymerase
7. Direct-acting Antiviral Drug Market, by Indication
7.1. Introduction
7.2. HIV Infection/ AIDS
7.3. Hepatitis C Virus
7.4. Influenza
7.5. Prophylaxis
8. Direct-acting Antiviral Drug Market, by Route
8.1. Introduction
8.2. Intravenous
8.3. Oral
8.4. Subcutaneous
8.5. Topical
9. Direct-acting Antiviral Drug Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacy
9.3. Online Drug Store
9.4. Retail Pharmacy
10. Americas Direct-acting Antiviral Drug Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Direct-acting Antiviral Drug Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
12. Europe, Middle East & Africa Direct-acting Antiviral Drug Market
12.1. Introduction
12.2. France
12.3. Germany
12.4. Italy
12.5. Netherlands
12.6. Qatar
12.7. Russia
12.8. Saudi Arabia
12.9. South Africa
12.10. Spain
12.11. United Arab Emirates
12.12. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis
13.3. Market Share Analysis, By Key Player
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion
14. Company Usability Profiles
14.1. A-S Medication Solutions
14.2. Actavis Group Ptc Ehf.
14.3. Agouron Pharmaceuticals
14.4. Aizant Drug Research Solutions Pvt Ltd
14.5. Amneal Pharmaceuticals LLC
14.6. Apotex Corporation
14.7. Atea Pharmaceuticals, Inc.
14.8. Auro Pharma Inc
14.9. Boehringer Ingelheim Pharmaceuticals Inc.
14.10. Bristol-Myers Squibb Company
14.11. Camber Pharmaceuticals, Inc.
14.12. Cipla USA Inc.
14.13. E.R. Squibb & Sons, L.L.C.
14.14. F. Hoffmann-La Roche
14.15. Genentech, Inc.
14.16. H.J. Harkins Company
14.17. Jamp Pharma Corporation
14.18. Marcan Pharmaceuticals Inc
14.19. Merck Ltd.
14.20. Mylan N.V.
14.21. New American Therapeutics, Inc
14.22. Novartis
14.23. PD-Rx Pharmaceuticals, Inc.
14.24. Pfizer Inc.
14.25. Physicians Total Care, Inc.
14.26. Prestium Pharma, Inc.
14.27. Remedy Repack
14.28. Sciegen Pharmaceuticals Inc.
14.29. Teva Pharmaceuticals USA, Inc.
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing
List of Figures
FIGURE 1. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2020 VS 2026 (USD MILLION)
FIGURE 2. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 3. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET: MARKET DYNAMICS
FIGURE 4. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2020 VS 2026 (%)
FIGURE 5. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2020 VS 2026 (USD MILLION)
FIGURE 6. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2026
FIGURE 7. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY NS3/4A PROTEASE, 2018-2026 (USD MILLION)
FIGURE 8. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY NS3/4A PROTEASE, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 9. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY NS5A PROTEIN, 2018-2026 (USD MILLION)
FIGURE 10. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY NS5A PROTEIN, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 11. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY NS5B RNA-DEPENDENT RNA POLYMERASE, 2018-2026 (USD MILLION)
FIGURE 12. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY NS5B RNA-DEPENDENT RNA POLYMERASE, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 13. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2020 VS 2026 (%)
FIGURE 14. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2020 VS 2026 (USD MILLION)
FIGURE 15. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2026
FIGURE 16. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HIV INFECTION/ AIDS, 2018-2026 (USD MILLION)
FIGURE 17. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HIV INFECTION/ AIDS, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 18. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS C VIRUS, 2018-2026 (USD MILLION)
FIGURE 19. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS C VIRUS, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 20. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INFLUENZA, 2018-2026 (USD MILLION)
FIGURE 21. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INFLUENZA, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 22. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PROPHYLAXIS, 2018-2026 (USD MILLION)
FIGURE 23. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PROPHYLAXIS, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 24. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2020 VS 2026 (%)
FIGURE 25. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2020 VS 2026 (USD MILLION)
FIGURE 26. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2026
FIGURE 27. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INTRAVENOUS, 2018-2026 (USD MILLION)
FIGURE 28. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INTRAVENOUS, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 29. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ORAL, 2018-2026 (USD MILLION)
FIGURE 30. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ORAL, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 31. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY SUBCUTANEOUS, 2018-2026 (USD MILLION)
FIGURE 32. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 33. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TOPICAL, 2018-2026 (USD MILLION)
FIGURE 34. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TOPICAL, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 35. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2020 VS 2026 (%)
FIGURE 36. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2020 VS 2026 (USD MILLION)
FIGURE 37. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2026
FIGURE 38. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2026 (USD MILLION)
FIGURE 39. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 40. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ONLINE DRUG STORE, 2018-2026 (USD MILLION)
FIGURE 41. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ONLINE DRUG STORE, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 42. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY RETAIL PHARMACY, 2018-2026 (USD MILLION)
FIGURE 43. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 44. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 45. ARGENTINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 46. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 47. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 48. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 49. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 50. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 51. AUSTRALIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 52. CHINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 53. INDIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 54. INDONESIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 55. JAPAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 56. MALAYSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 57. PHILIPPINES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 58. SINGAPORE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 59. SOUTH KOREA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 60. TAIWAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 61. THAILAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 62. EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 63. FRANCE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 64. GERMANY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 65. ITALY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 66. NETHERLANDS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 67. QATAR DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 68. RUSSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 69. SAUDI ARABIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 70. SOUTH AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 71. SPAIN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 72. UNITED ARAB EMIRATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 73. UNITED KINGDOM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 74. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET: FPNV POSITIONING MATRIX
FIGURE 75. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET: SHARE, BY KEY PLAYER, 2020
FIGURE 76. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET, BY TYPE
List of Tables
TABLE 1. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016–2020
TABLE 3. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 4. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD MILLION)
TABLE 5. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY NS3/4A PROTEASE, BY REGION, 2018-2026 (USD MILLION)
TABLE 6. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY NS5A PROTEIN, BY REGION, 2018-2026 (USD MILLION)
TABLE 7. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY NS5B RNA-DEPENDENT RNA POLYMERASE, BY REGION, 2018-2026 (USD MILLION)
TABLE 8. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2026 (USD MILLION)
TABLE 9. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HIV INFECTION/ AIDS, BY REGION, 2018-2026 (USD MILLION)
TABLE 10. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS C VIRUS, BY REGION, 2018-2026 (USD MILLION)
TABLE 11. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2026 (USD MILLION)
TABLE 12. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PROPHYLAXIS, BY REGION, 2018-2026 (USD MILLION)
TABLE 13. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2026 (USD MILLION)
TABLE 14. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2026 (USD MILLION)
TABLE 15. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ORAL, BY REGION, 2018-2026 (USD MILLION)
TABLE 16. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2026 (USD MILLION)
TABLE 17. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TOPICAL, BY REGION, 2018-2026 (USD MILLION)
TABLE 18. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD MILLION)
TABLE 19. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2026 (USD MILLION)
TABLE 20. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ONLINE DRUG STORE, BY REGION, 2018-2026 (USD MILLION)
TABLE 21. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2026 (USD MILLION)
TABLE 22. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 23. ARGENTINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 24. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 25. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 26. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 27. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 28. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 29. AUSTRALIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 30. CHINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 31. INDIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 32. INDONESIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 33. JAPAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 34. MALAYSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 35. PHILIPPINES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 36. SINGAPORE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 37. SOUTH KOREA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 38. TAIWAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 39. THAILAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 40. EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 41. FRANCE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 42. GERMANY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 43. ITALY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 44. NETHERLANDS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 45. QATAR DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 46. RUSSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 47. SAUDI ARABIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 48. SOUTH AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 49. SPAIN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 50. UNITED ARAB EMIRATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 51. UNITED KINGDOM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 52. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET: SCORES
TABLE 53. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET: BUSINESS STRATEGY
TABLE 54. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET: PRODUCT SATISFACTION
TABLE 55. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET: RANKING
TABLE 56. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET: SHARE, BY KEY PLAYER, 2020
TABLE 57. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET: MERGER & ACQUISITION
TABLE 58. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 59. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 60. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET: INVESTMENT & FUNDING
TABLE 61. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 62. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET: LICENSE & PRICING

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook